查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1923034

黏性補充劑注射市場按產品類型、應用部位、患者年齡層、最終用戶和分銷管道分類－2026-2032年全球預測

Viscosupplementation Injection Market by Product Type, Application Site, Patient Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，黏性補充劑注射劑市場價值將達到 37.2 億美元，到 2026 年將成長至 39.8 億美元，到 2032 年將達到 60.5 億美元，年複合成長率為 7.17%。

關鍵市場統計數據
基準年 2025 37.2億美元
預計年份：2026年 39.8億美元
預測年份 2032 60.5億美元
複合年成長率 (%) 7.17%

黏性補充注射療法的簡要概述：當代肌肉骨骼護理中不斷發展的臨床實踐和相關人員的優先事項

黏液補充注射已成為多種肌肉骨骼疾病治療方案中的重要選擇，尤其適用於緩解骨關節炎的症狀。這些治療方法利用透明質酸製劑來恢復關節的黏彈性，減輕疼痛，並改善尋求全身用藥和手術替代方案的患者的功能。臨床醫生越來越重視將黏液補充注射作為多方面治療策略的一部分，該策略還包括物理治療、體重管理和輔助藥物治療。這種綜合觀點正在改變醫療機構的關節內粘稠補充療法模式。

檢驗了技術、臨床實踐和治療模式方面意義深遠的變革，這些變革將重新定義關節內粘稠補充療法療法的開發和應用方式，以及其在治療路徑中的地位。

在關節內粘稠補充療法，引發了臨床醫生對作用持續時間和操作負擔的更多討論，促使他們重新評估治療流程，並將創新療法與傳統方法相結合。同時，影像和照護現場診斷技術的進步也提高了關節內注射的準確性和可重複性，從而促進了其在診所和門診中心的廣泛應用。

評估2025年美國關稅如何重塑關節內粘稠補充療法相關人員的供應鏈、採購行為和商業性韌性策略

2025年美國關稅政策的實施，為關節內粘稠補充療法生態系統的採購、供應鏈設計和定價動態帶來了關鍵轉折點。傳統上依賴跨境進口半成品產品和成品的製造商正面臨不斷上漲的到岸成本和籌資策略日益嚴格的審查。因此，各企業正在加快近岸外包的步伐，尋找替代供應商，並最佳化材料清單，在確保產品完整性的前提下，優先考慮供應的連續性和合規性。

綜合細分分析揭示了產品化學成分、解剖應用部位、臨床環境、分銷管道、價格點和患者人口統計特徵如何影響產品採納趨勢和策略制定。

細分市場層面的趨勢揭示了產品類型、應用部位、最終用戶、分銷管道、價格點和患者群體等因素對臨床、採購和商業性的影響各不相同。交聯和非交聯透明質酸製劑之間的產品差異會影響臨床醫生的選擇和採購談判。交聯製劑通常強調延長作用時間和增加給藥頻率，而非交聯製劑則著重於操作簡便性和成本效益。髖關節、膝關節和肩關節等不同應用部位的差異，會為臨床通訊協定帶來更多細微差別。特別是膝關節，需要考慮關節腔的解剖結構，例如雙腔、三腔或單腔結構，這些因素會影響注射技術、證據要求和負責人訓練需求。

一項區域觀點，旨在揭示主要區域在法規環境、醫療服務模式和分銷趨勢方面的差異

區域環境對美洲、歐洲、中東和非洲以及亞太地區的臨床實踐模式、監管路徑和商業性策略有著顯著影響，每個地區都有其獨特的促進因素和限制因素。在美洲，完善的門診醫療基礎設施和日益重視的門診服務模式支撐著診所和門診手術中心（ASC）手術量的成長。同時，分散的支付方要求企業集中精力進行報銷工作並進行療效評估，以確保獲得有利的資金條件。在歐洲、中東和非洲地區，不同的管理體制和不均衡的報銷環境要求製造商和經銷商採用區域性的材料和證據包，並根據各國的醫療保健體系調整其市場進入策略。

策略競爭格局概述：重點闡述製劑創新、臨床證據項目和通路夥伴關係如何定義市場差異化和長期定位。

關節內粘稠補充療法領域的競爭格局並非簡單的商品競爭，而是透過配方科學、臨床證據和通路關係實現差異化。主要企業正優先建立穩固的市場地位，將專有化學技術、生產規模以及與臨床研究人員的持續合作相結合。與醫療設備製造商、影像設備供應商和臨床網路建立策略聯盟，有助於提供整合解決方案，從而擴大市場覆蓋範圍並確保手術效果的一致性。此外，各公司正增加對上市後證據（包括註冊研究和真實世界研究）的投入，以證明其療效，並支持與支付方和大型機構採購方的對話。

為商業、臨床和價值鏈領導者提供切實可行的策略藍圖，以增強韌性並加速在所有管道中採用價值主導模式。

產業領導者應採取一系列合作行動，以增強韌性、加速具有臨床意義的創新並提高商業性精準度。首先，多角化採購管道和提高生產冗餘度將有助於持續向大批量終端用戶供應產品，同時降低貿易中斷和關稅波動帶來的風險。其次，優先投資於長效製劑和針對特定部位需求的製劑平台，可以創造明顯的臨床優勢，並簡化患者和臨床醫師的治療方法。第三，利用可靠的真實世界數據和按效果付費的合約模式與支付方合作，可以促進更廣泛的藥物可及性，並將商業性獎勵與臨床療效掛鉤。

我們以透明的方式解釋我們多方面的調查方法，該方法結合了臨床醫生訪談、採購諮詢和第二手資料整合，以確保研究結果的可靠性和檢驗。

這些研究結果的基礎是將定性一手資料收集與嚴謹的二手資料分析和迭代檢驗相結合。一手數據包括對整形外科和風濕病臨床醫生、採購和供應鏈經理、門診中心運營人員以及藥屋主任的結構化訪談，以及與臨床教育工作者和支付方代表的匿名討論，以了解報銷壓力和證據要求。二手資料包括同行評審的臨床文獻、監管指南、產品標籤以及已發布的程序和實踐指南，並與一手反饋進行三角驗證，以確保其與時俱進並符合臨床實踐。

一份簡潔的策略要務概要，強調證據完整性、供應韌性和有針對性的商業化，以促進持續推廣。

總之，注射用黏性補充劑在現代肌肉骨骼護理中佔據戰略地位，其特點是配方創新迅速、給藥環境不斷變化以及採購需求持續發展。將臨床證據的產生與務實的經銷模式和具有彈性的供應鏈設計相結合的相關人員，將更有利於滿足臨床醫生的期望並應對支付方的審查。 2025年的關稅環境凸顯了製定更穩健的籌資策略和合約柔軟性的必要性，積極應對的企業將能夠在減輕短期干擾的同時，保持其長期的商業性發展勢頭。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按產品類型分類的黏性補充劑注射劑市場

  • 交聯玻尿酸
  • 非交聯玻尿酸

9. 按應用部位分類的黏性補充劑注射劑市場

  • 髖關節
  • 膝蓋
    • 雙腔型
    • 三室型
    • 單人房
  • 肩關節

第10章 依患者年齡層分類的黏性補充劑注射劑市場

  • 成人
  • 老年
  • 老年人

第11章 按最終用戶分類的黏性補充劑注射劑市場

  • 門診手術中心
  • 診所
    • 整形外科診所
    • 風濕病診所
  • 醫院

12. 按分銷管道分類的黏性補充劑注射劑市場

  • 醫院藥房
  • 網路藥房
  • 零售藥房

13. 各地區黏性補充劑注射劑市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 黏性補充劑注射市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國黏性補充劑注射劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國黏性補充劑注射劑市場

第17章：中國黏性補充劑注射劑市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Anika Therapeutics, Inc.
  • Bioiberica SAU
  • Bioventus, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Diaco Biofarmaceutici Srl
  • Ferring Pharmaceuticals A/S
  • Fidia Farmaceutici SpA
  • Hoffmann-La Roche Ltd.
  • I+MED Srl
  • IBSA Institut Biochimique SA
  • IBSA Poland sp. z oo
  • Johnson & Johnson
  • Kyowa Hakko Kirin Co., Ltd.
  • LG Chem Ltd.
  • Maxigen Biotech Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Sanofi SA
  • SEIKAGAKU CORPORATION
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-867BED9A9EDB

The Viscosupplementation Injection Market was valued at USD 3.72 billion in 2025 and is projected to grow to USD 3.98 billion in 2026, with a CAGR of 7.17%, reaching USD 6.05 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.72 billion
Estimated Year [2026] USD 3.98 billion
Forecast Year [2032] USD 6.05 billion
CAGR (%) 7.17%

Concise contextual overview of viscosupplementation injections situating clinical practice evolution and stakeholder priorities within contemporary musculoskeletal care

Viscosupplementation injections have become an integral therapeutic option within the broader musculoskeletal care pathway, particularly for symptomatic relief of osteoarthritic joints. These interventions leverage hyaluronic acid formulations to restore viscoelastic joint properties, reduce pain, and improve function in patients who may be seeking alternatives to systemic pharmacotherapy or surgical intervention. Clinicians increasingly view viscosupplementation as part of a multimodal care strategy that includes physical therapy, weight management, and adjunctive pharmacologic approaches, and this integrated perspective is reshaping adoption patterns across care settings.

At the same time, technological refinement in formulation chemistry, imaging-guided injection techniques, and delivery devices has elevated expectations for efficacy, durability, and procedural consistency. Reimbursement and procurement practices across hospitals, ambulatory surgery centers, and clinics are evolving in response to these clinical advances and the shifting preferences of patients and payors. Consequently, stakeholders from manufacturers to institution procurement teams are recalibrating product positioning, clinical education, and distribution strategies to align with contemporary clinical workflows and value-based care imperatives.

Examination of sweeping technological, clinical practice, and delivery model shifts that are redefining how viscosupplementation is developed, delivered, and positioned in care pathways

The viscosupplementation landscape is experiencing transformative shifts driven by scientific innovation, procedural diffusion, and changing healthcare delivery models. Advances in cross-linking chemistry and formulation stability have extended clinical conversations around duration of action and procedural burden, prompting clinicians to reassess treatment algorithms and integrate newer options alongside traditional modalities. Parallel to formulation innovation, improvements in imaging and point-of-care diagnostics have increased the precision and reproducibility of intra-articular injections, which in turn supports wider uptake in office-based settings and ambulatory centers.

Concurrently, service delivery is moving toward decentralized settings where ambulatory surgery centers and specialty clinics assume a larger procedural role, supported by streamlined inventory and standardized training programs. Payers and providers are also emphasizing measurable patient outcomes, driving manufacturers to invest in real-world evidence generation and registries that demonstrate sustained functional benefit. These intersecting trends are reshaping commercial models, with a clear focus on evidence-driven differentiation, channel diversification, and clinical education to support safe, consistent, and cost-effective care pathways.

Assessment of how 2025 United States tariff measures have reconfigured supply chains, procurement behavior, and commercial resilience strategies for viscosupplementation stakeholders

The introduction of United States tariffs in 2025 has created a material inflection point for procurement, supply chain design, and pricing dynamics across the viscosupplementation ecosystem. Manufacturers that historically relied on cross-border intermediate goods and finished product imports have faced elevated landed costs and increased scrutiny of sourcing strategies. As a result, organizations are accelerating nearshoring initiatives, qualifying alternative suppliers, and optimizing bill-of-materials in ways that prioritize continuity of supply and regulatory compliance without compromising product integrity.

For providers and distributors, the tariff environment has heightened the importance of contractual agility and inventory management. Hospitals and clinics are renegotiating procurement terms, extending evaluation of domestic supply options, and seeking longer-term supplier assurances to mitigate exposure to tariff-driven cost variability. From a strategic perspective, these conditions have stimulated investment in manufacturing redundancy, reshaped distribution channel economics, and intensified conversations about value-based purchasing where outcomes-linked agreements can help absorb transient input-cost shocks. Collectively, the tariff changes have forced stakeholders to be more deliberate about supplier diversification, total landed cost transparency, and the resilience of commercial contracts.

Integrated segmentation analysis illuminating how product chemistry, anatomical application, clinical setting, distribution channels, pricing tiers, and patient age cohorts shape adoption and strategy

Segment-level dynamics reveal distinct clinical, procurement, and commercial implications across product types, application sites, end users, distribution channels, price tiers, and patient age groups. Product differentiation between cross-linked hyaluronic acid and non-cross-linked formulations influences clinician choice and procurement negotiations because cross-linked chemistries generally emphasize extended residence time and dosing frequency considerations while non-cross-linked options may be positioned around procedural simplicity and cost sensitivity. Application site variation, spanning hip, knee, and shoulder interventions, further nuances clinical protocols; the knee in particular requires attention to compartmental anatomy with bicompartmental, tricompartmental, or unicompartmental designations shaping injection technique, evidence requirements, and training needs for injectors.

End-user segmentation underscores divergent purchasing behavior and procedural workflows across ambulatory surgery centers, clinics, and hospitals, with clinics requiring tailored outreach depending on whether they are orthopedic or rheumatology focused. Distribution channel distinctions are equally consequential; hospital pharmacies, online pharmacies, and retail pharmacies each present different stocking models and regulatory touchpoints, and the growth of online pharmacies-both manufacturer direct portals and third-party e-commerce platforms-has introduced new considerations around authenticity, cold chain integrity, and service-level expectations. Price-tier stratification into economy, mid tier (standard and value), and premium offerings demands a coherent value narrative that aligns clinical outcomes with cost expectations. Finally, patient age group categories-adults, elderly, and geriatric-inform product selection and communication strategies because comorbidity burden, treatment goals, and tolerability profiles shift with age. Integrating these segmentation axes enables more granular product positioning, targeted evidence generation, and channel-specific commercial plans that resonate with clinical and procurement stakeholders.

Comparative regional perspective that captures how regulatory environments, care delivery models, and distribution dynamics diverge across major global regions

Regional contexts substantially influence clinical practice patterns, regulatory pathways, and commercial approaches across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting unique enablers and constraints. In the Americas, robust outpatient infrastructure and a growing emphasis on ambulatory care delivery support expanded procedural volumes in clinics and ASCs, while payor fragmentation necessitates focused reimbursement engagement and outcome measurement to secure favorable procurement terms. Transitioning to Europe, Middle East & Africa, stakeholders encounter diverse regulatory regimes and heterogenous reimbursement environments, prompting manufacturers and distributors to adopt region-specific dossiers and evidence packages while calibrating market entry sequences to align with national health systems.

In the Asia-Pacific region, rapid urbanization, increased surgical capacity, and an expanding middle-aged population are driving demand for minimally invasive orthopedic interventions; however, the region also presents a complex mix of regulatory standards and local manufacturing capabilities that influence sourcing and partnership strategies. Across all regions, digital distribution channels and telehealth-enabled patient engagement are altering how education and follow-up care are delivered, and regional leadership must therefore balance global platform consistency with local customization to address clinician workflows, procurement practices, and patient expectations effectively.

Strategic competitive overview emphasizing how formulation innovation, clinical evidence programs, and channel partnerships define market differentiation and long-term positioning

Competitive dynamics in the viscosupplementation space are characterized by differentiation through formulation science, clinical evidence, and channel relationships rather than by commodity-based competition alone. Leading firms prioritize a blend of proprietary chemistry, manufacturing scale, and sustained clinical-investigator engagement to build defensible positions. Strategic alliances with device manufacturers, imaging vendors, and clinical networks amplify market reach and support integrated solutions that facilitate consistent procedural outcomes. Moreover, companies are increasingly investing in post-market evidence generation, including registries and real-world outcomes studies, to demonstrate comparative effectiveness and to support dialogue with payors and large institutional purchasers.

At the commercial interface, differentiation often hinges on the ability to provide comprehensive training, procedural support, and supply reliability to ambulatory centers and specialty clinics. Firms that can couple clinical education with streamlined distribution and transparent pricing tend to secure deeper clinical partnerships and recurring demand. Intellectual property around cross-linking methods and delivery systems can raise barriers to entry, but market incumbents must remain vigilant about biosimilar and alternative therapy developments that target specific niches. Ultimately, sustainable competitive advantage will depend on aligning R&D priorities with demonstrable clinical value and scalable commercialization pathways that reflect evolving provider and payer expectations.

Action-oriented strategic roadmap for commercial, clinical, and supply chain leaders to fortify resilience and accelerate value-driven adoption across channels

Industry leaders should pursue a coordinated set of actions that strengthen resilience, accelerate clinically meaningful innovation, and enhance commercial precision. First, diversifying sourcing and increasing manufacturing redundancy will reduce exposure to trade disruptions and tariff volatility while supporting continuity for high-volume end users. Second, prioritizing investment in longer-acting formulations and formulation platforms that address specific compartmental needs can create distinct clinical advantages and simplify treatment regimens for both patients and clinicians. Third, engaging payors with robust real-world evidence and outcomes-based contracting models can facilitate broader access and align commercial incentives with clinical effectiveness.

In parallel, companies should expand training programs that target office-based clinicians and ambulatory centers, integrating imaging best practices and standardized protocols to improve procedural consistency. Enhancing direct-to-provider and digital distribution capabilities will improve channel economics and patient access, particularly when combined with clear value propositions across economy, mid tier, and premium price points. Finally, regional go-to-market strategies should be customized to account for regulatory idiosyncrasies and procurement models, and leadership teams should implement continuous scenario planning to respond rapidly to policy or supply-chain shifts.

Transparent description of the multi-method research approach combining clinician interviews, procurement consultations, and secondary synthesis to ensure robust, validated insights

The research underpinning these insights combined qualitative primary engagement with rigorous secondary synthesis and iterative validation. Primary inputs included structured interviews with orthopedic and rheumatology clinicians, procurement and supply chain managers, ambulatory center operators, and pharmacy directors, supplemented by anonymized discussions with clinical educators and payor representatives to understand reimbursement pressures and evidence expectations. Secondary inputs consisted of peer-reviewed clinical literature, regulatory guidance, product labeling, and publicly available procedural and practice guidelines, which were triangulated against primary feedback to ensure contemporary relevance and clinical fidelity.

Data synthesis followed a layered approach: segmentation frameworks were developed and stress-tested against clinician workflows and purchaser decision criteria; thematic analysis identified recurring operational and commercial pain points; and the resultant findings were validated through follow-up consultations with key informants. Methodological limitations included variability in local reimbursement practices and the evolving nature of post-market evidence; these were mitigated by purposive sampling across regions, care settings, and stakeholder types to capture a breadth of perspectives and to surface robust, actionable conclusions.

Concise synthesis of strategic imperatives emphasizing evidence alignment, supply resilience, and targeted commercialization to drive sustainable adoption

In summary, viscosupplementation injections occupy a strategic position within contemporary musculoskeletal care, characterized by rapid formulation innovation, shifting delivery settings, and increasingly sophisticated procurement expectations. Stakeholders who align clinical evidence generation with pragmatic distribution models and resilient supply-chain designs will be best positioned to meet clinician expectations and to navigate payer scrutiny. The 2025 tariff environment has underscored the necessity for more robust sourcing strategies and contractual flexibility, and organizations that respond proactively will mitigate short-term disruption while protecting long-term commercial momentum.

Ultimately, the path forward requires coordinated investment in product differentiation, outcome measurement, and targeted commercial execution across segmented customer groups and regional contexts. By emphasizing clinician training, focused evidence programs, and tailored distribution approaches, manufacturers and channel partners can accelerate adoption where clinical need and operational readiness align, delivering improved patient experiences while meeting institutional performance and cost objectives.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Viscosupplementation Injection Market, by Product Type

  • 8.1. Cross Linked Hyaluronic Acid
  • 8.2. Non Cross Linked Hyaluronic Acid

9. Viscosupplementation Injection Market, by Application Site

  • 9.1. Hip
  • 9.2. Knee
    • 9.2.1. Bicompartmental
    • 9.2.2. Tricompartmental
    • 9.2.3. Unicompartmental
  • 9.3. Shoulder

10. Viscosupplementation Injection Market, by Patient Age Group

  • 10.1. Adults
  • 10.2. Elderly
  • 10.3. Geriatric

11. Viscosupplementation Injection Market, by End User

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Clinics
    • 11.2.1. Orthopedic Clinics
    • 11.2.2. Rheumatology Clinics
  • 11.3. Hospitals

12. Viscosupplementation Injection Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Viscosupplementation Injection Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Viscosupplementation Injection Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Viscosupplementation Injection Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Viscosupplementation Injection Market

17. China Viscosupplementation Injection Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Anika Therapeutics, Inc.
  • 18.6. Bioiberica S.A.U.
  • 18.7. Bioventus, Inc.
  • 18.8. Chugai Pharmaceutical Co., Ltd.
  • 18.9. Diaco Biofarmaceutici S.r.l.
  • 18.10. Ferring Pharmaceuticals A/S
  • 18.11. Fidia Farmaceutici S.p.A.
  • 18.12. Hoffmann-La Roche Ltd.
  • 18.13. I+MED S.r.l.
  • 18.14. IBSA Institut Biochimique SA
  • 18.15. IBSA Poland sp. z o.o.
  • 18.16. Johnson & Johnson
  • 18.17. Kyowa Hakko Kirin Co., Ltd.
  • 18.18. LG Chem Ltd.
  • 18.19. Maxigen Biotech Inc.
  • 18.20. Ono Pharmaceutical Co., Ltd.
  • 18.21. Sanofi S.A.
  • 18.22. SEIKAGAKU CORPORATION
  • 18.23. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES VISCOSUPPLEMENTATION INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CROSS LINKED HYALURONIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CROSS LINKED HYALURONIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CROSS LINKED HYALURONIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY NON CROSS LINKED HYALURONIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY NON CROSS LINKED HYALURONIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY NON CROSS LINKED HYALURONIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY HIP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY HIP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY HIP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY BICOMPARTMENTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY BICOMPARTMENTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY BICOMPARTMENTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY TRICOMPARTMENTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY TRICOMPARTMENTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY TRICOMPARTMENTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY UNICOMPARTMENTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY UNICOMPARTMENTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY UNICOMPARTMENTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY SHOULDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY SHOULDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY SHOULDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY ELDERLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY ELDERLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY ELDERLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY ORTHOPEDIC CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY ORTHOPEDIC CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY ORTHOPEDIC CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY RHEUMATOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY RHEUMATOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY RHEUMATOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GCC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 144. GCC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GCC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GCC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 147. GCC VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. G7 VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 167. G7 VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 168. G7 VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. G7 VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. G7 VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 171. G7 VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. NATO VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 176. NATO VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. NATO VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. NATO VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 179. NATO VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES VISCOSUPPLEMENTATION INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY KNEE, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA VISCOSUPPLEMENTATION INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)